Article in The Journal of pharmacology and experimental therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 9 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
3 authors at 1 institution in 1 country.
Roberta AvvisatoDepartment of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Einstein Institute for Aging Research (R.A., S.S.J., G.S.) and Department of Molecular Pharmacology, Institute for Neuroimmunology and Inflammation, Fleischer Institute for Diabetes and Metabolism (FIDAM) (G.S.), Albert Einstein College of Medicine, New York, New York.
Stanislovas S JankauskasDepartment of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Einstein Institute for Aging Research (R.A., S.S.J., G.S.) and Department of Molecular Pharmacology, Institute for Neuroimmunology and Inflammation, Fleischer Institute for Diabetes and Metabolism (FIDAM) (G.S.), Albert Einstein College of Medicine, New York, New York.
Gaetano SantulliDepartment of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Einstein Institute for Aging Research (R.A., S.S.J., G.S.) and Department of Molecular Pharmacology, Institute for Neuroimmunology and Inflammation, Fleischer Institute for Diabetes and Metabolism (FIDAM) (G.S.), Albert Einstein College of Medicine, New York, New York gsantulli001@gmail.com.ORCID 0000-0001-7231-375X
Albert Einstein College of Medicine · US
Funding
CTSA Administrative Supplement for Informatics Core: A novel AI/ML system to predict respiratory failure and ARDS in Covid-19 patientsUL1TR002556 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, KIM, MIMI Y · 2018 to 2022
$26.7M
REGULATION OF THE INSULIN RECEPTOR KINASER01DK033823 · NIDDK · UNIVERSITY OF IOWA · PI KURLAND, IRWIN JACK, PESSIN, JEFFREY E. · 1986 to 2022
$6.7M
Modulation of Mitofusin Activity to Treat Heart DiseaseR01HL159062 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI KITSIS, RICHARD N · 2021 to 2024
$2.6M
Caspase-9 as a nodal point connecting necrotic and apoptotic cell death in myocardial infarctionR01HL164772 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI KITSIS, RICHARD N · 2022 to 2025
$2.5M
Functional role of IP3 receptors in the regulation of cardiac myofibroblastsR01HL146691 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SANTULLI, GAETANO · 2019 to 2023
$2.1M
Mechanisms of cardiovascular diseaseT32HL144456 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Carlos Jose Rodriguez, Nicholas E Sibinga · 2019 to 2026
$1.9M
Beta Cell Intracellular Calcium and DiabetesR01DK123259 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SANTULLI, GAETANO · 2020 to 2023
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Istaroxime and Beyond: New Therapeutic Strategies to Specifically Activate SERCA and Treat Heart Failure. · full record | OpenQuestion